Tiziana life sciences doses first patient in phase 2a trial of intranasal foralumab in multiple sclerosis
New york, dec. 19, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-spms). six investigational centers have been recruited for this double-blind, placebo-controlled trial, with up to 18 patients per treatment arm. the primary endpoint of the trial will be the change in microglial activation based on pet scans. clinical evaluations include the expanded disability status scale (edss), qol assessments, and the modified fatigue impact scale (mfis), which assess parameters that are essential to a patient's everyday life. novel immuno-biomarkers will be measured also and assessed for predictive relevance. central review of pet scans and images is an integral component of this study.
TLSA Ratings Summary
TLSA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission